Evergreen Therapeutics announced that EG-301, an oral small-molecule candidate developed for dry age-related macular degeneration (dry AMD), has demonstrated both an acceptable safety profile and preliminary efficacy in attenuating disease progression in preclinical animal studies. The compound was developed through company’s proprietary AI platform. These data will form the core of the investigational new drug (IND) submission to the U.S. Food and Drug Administration (FDA).
Dry AMD, the non‑exudative form of age‑related macular degeneration, is a chronic, progressive and currently irreversible retinal disorder that primarily affects individuals over 50. The condition leads to degeneration and death of retinal cells, resulting in vision loss. Estimates indicate that approximately 100 million people worldwide were affected by macular degeneration in 2020, with dry AMD accounting for about 90% of cases. To date, there are no approved therapies for this indication.